

## Learner Notification

---

Total Health Conferences New and Supporting Data for Optimizing Therapy in HER2+ Breast Cancer July 24, 2021 Date of CE Release: 07-24-2021 Date of CE Expiration: 07-24-2022 Location: Online

### **Acknowledgement of Financial Commercial Support**

No financial commercial support was received for this educational activity.

### **Acknowledgement of In-Kind Commercial Support**

No in-kind commercial support was received for this educational activity.

### **Satisfactory Completion**

Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles, and complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. You must participate in the entire activity as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.



### **Joint Accreditation Statement**

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Total Health Conferences. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

### **Physicians**

Amedco LLC designates this material for a maximum of 1.0 *AMA PRA Category 1 Credits™* for physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### **Pharmacists**

Amedco LLC designates this activity for a maximum of 1.0 knowledge-based CPE contact hours.

### **Nurses**

Amedco LLC designates this activity for a maximum of 1.0 ANCC contact hours.

### **Objectives - After Attending This Program You Should Be Able To**

1. Review neoadjuvant and adjuvant treatment strategies in HER2 positive breast cancer

2. Review and discuss the unmet need of brain metastasis in HER2 positive breast cancer
3. Review existing and newly approved treatment options in the metastatic setting like trastuzumab deruxtecan, tucatinib and agents in development

## Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-6.2, 6.5)

All individuals in a position to control the content of CE are listed in the program book. If their name is not listed below, they disclosed that they had no financial relationships with a commercial interest.

<b>Name</b>	<b>Commercial Interest:Relationship</b>
virginia kaklamani	genentech, novartis, astrazeneka, puma:Consultant gilead, seagen, daichi:Speakers Bureau
Ruth O'Regan	Pfizer, Lilly, Novartis, Biotheranostics, Immunomedics, PUMA, Seagen, Genentech, Macrogenics:Consultant

## How to Get Your Certificate

1. CME Link: <https://workshop-evaluator.herokuapp.com/evaluation/9330>
  2. Evaluate the meeting.
  3. Print, download, or save your certificate for your records.
-

